Current therapeutic options for managing familial Mediterranean fever

Bibliography

• Ben-Chetrit E, Touitou I. Familial mediterranean Fever in the world. Arthritis Rheum 2009;61(10):1447-53
   PubMed Web of Science ®Google Scholar
• The International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 1997;90(4):797-807
   PubMed Web of Science ®Google Scholar
• French FMFC. A candidate gene for familial Mediterranean fever. Nat Genet 1997;17(1):25-31
   PubMed Web of Science ®Google Scholar
• Chae JJ, Aksentijevich I, Kastner DL. Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy. Br J Haematol 2009;146(5):467-78
   PubMed Web of Science ®Google Scholar
• Stojanov S, Kastner DL. Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr Opin Rheumatol 2005;17(5):586-99
   PubMed Web of Science ®Google Scholar
• Goldfinger SE. Colchicine for familial Mediterranean fever. N Engl J Med 1972;287(25):1302
   PubMed Web of Science ®Google Scholar
• Hartung EF. History of the use of colchicum and related medicaments in gout; with suggestions for further research. Ann Rheum Dis 1954;13(3):190-200
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Wolff SM, Goldfinger SE, et al. Colchicine therapy for familial mediterranean fever. A double-blind trial. N Engl J Med 1974;291(18):934-7
   PubMed Web of Science ®Google Scholar
• Zemer D, Revach M, Pras M, et al. A controlled trial of colchicine in preventing attacks of familial mediterranean fever. N Engl J Med 1974;291(18):932-4
   PubMed Web of Science ®Google Scholar
• Duzova A, Bakkaloglu A, Besbas N, et al. Role of A-SAA in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever. Clin Exp Rheumatol 2003;21(4):509-14
   PubMed Web of Science ®Google Scholar
• Ozcakar ZB, Yalcinkaya F, Yuksel S, et al. Possible effect of subclinical inflammation on daily life in familial Mediterranean fever. Clin Rheumatol 2006;25(2):149-52
   PubMed Web of Science ®Google Scholar
• Ozaltin F, Bilginer Y, Gulhan B, et al. Diagnostic validity of colchicine in patients with Familial Mediterranean fever. Clin Rheumatol 2014;33(7):969-74
   PubMed Web of Science ®Google Scholar
• Livneh A, Langevitz P, Zemer D, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 1997;40(10):1879-85
   PubMed Web of Science ®Google Scholar
• Ravelli RB, Gigant B, Curmi PA, et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 2004;428(6979):198-202
   PubMed Web of Science ®Google Scholar
• Ben-Chetrit E, Bergmann S, Sood R. Mechanism of the anti-inflammatory effect of colchicine in rheumatic diseases: a possible new outlook through microarray analysis. Rheumatology (Oxford) 2006;45(3):274-82
   PubMed Web of Science ®Google Scholar
• Cerquaglia C, Diaco M, Nucera G, et al. Pharmacological and clinical basis of treatment of Familial Mediterranean Fever (FMF) with colchicine or analogues: an update. Curr Drug Targets Inflamm Allergy 2005;4(1):117-24
   PubMedGoogle Scholar
• Cronstein BN, Terkeltaub R. The inflammatory process of gout and its treatment. Arthritis Res Ther 2006;8(Suppl 1):S3
   PubMed Web of Science ®Google Scholar
• Taskiran EZ, Cetinkaya A, Balci-Peynircioglu B, et al. The effect of colchicine on pyrin and pyrin interacting proteins. J Cell Biochem 2012;113(11):3536-46
   PubMed Web of Science ®Google Scholar
• Shohat M, Halpern GJ. Familial Mediterranean fever--a review. Genet Med 2011;13(6):487-98
   PubMed Web of Science ®Google Scholar
• Zemer D, Livneh A, Danon YL, et al. Long-term colchicine treatment in children with familial Mediterranean fever. Arthritis Rheum 1991;34(8):973-7
   PubMed Web of Science ®Google Scholar
• Hentgen V, Grateau G, Kone-Paut I, et al. Evidence-based recommendations for the practical management of Familial Mediterranean Fever. Semin Arthritis Rheum 2013;43(3):387-91
   PubMed Web of Science ®Google Scholar
• Kallinich T, Haffner D, Niehues T, et al. Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics 2007;119(2):e474-83
   PubMed Web of Science ®Google Scholar
• Padeh S, Gerstein M, Berkun Y. Colchicine is a safe drug in children with familial Mediterranean fever. J Pediatr 2012;161(6):1142-6
   PubMed Web of Science ®Google Scholar
• Wason S, DiGiacinto JL, Davis MW. Effects of grapefruit and Seville orange juices on the pharmacokinetic properties of colchicine in healthy subjects. Clin Ther 2012;34(10):2161-73
   PubMed Web of Science ®Google Scholar
• Diav-Citrin O, Shechtman S, Schwartz V, et al. Pregnancy outcome after in utero exposure to colchicine. Am J Obstet Gynecol 2010;203(2):144 e1-6
   PubMed Web of Science ®Google Scholar
• Terkeltaub RA. Colchicine update: 2008. Sem Arthritis Rheum 2009;38(6):411-19
   PubMed Web of Science ®Google Scholar
• Jayaprakash V, Ansell G, Galler D. Colchicine overdose: the devil is in the detail. N Z Med J 2007;120(1248):U2402
   PubMedGoogle Scholar
• Varughese GI, Varghese AI, Tahrani AA. Colchicine: time to rethink. N Z Med J 2007;120(1249):U2429
   Google Scholar
• Cocco G, Chu DC, Pandolfi S. Colchicine in clinical medicine. A guide for internists. Eur J Int Med 2010;21(6):503-8
   PubMed Web of Science ®Google Scholar
• Fradkin A, Yahav J, Zemer D, Jonas A. Colchicine-induced lactose malabsorption in patients with familial Mediterranean fever. Isr J Med Sci 1995;31(10):616-20
   PubMedGoogle Scholar
• Malkinson FD, Lynfield YL. Colchicine alopecia. J Invest Dermatol 1959;33:371-84
   PubMed Web of Science ®Google Scholar
• Yilmaz R OS, Ozyurt H, Erkorkmaz U. Serum vitamin B12 status in children with familial Mediterranean fever receiving colchicine treatment. HK J Paediatr 2011;16:3-8
   Web of Science ®Google Scholar
• Choi SS, Chan KF, Ng HK, Mak WP. Colchicine-induced myopathy and neuropathy. Hong Kong Med J 1999;5(2):204-7
   PubMedGoogle Scholar
• Ben-Chetrit E, Backenroth R, Haimov-Kochman R, Pizov G. Azoospermia in familial Mediterranean fever patients: the role of colchicine and amyloidosis. Ann Rheum Dis 1998;57(4):259-60
   PubMed Web of Science ®Google Scholar
• Ben-Chetrit E, Navon P. Colchicine-induced leukopenia in a patient with familial Mediterranean fever: the cause and a possible approach. Clin Exp Rheumatol 2003;21(4 Suppl 30):S38-40
   Google Scholar
• Ben-Chetrit E, Levy M. Reproductive system in familial Mediterranean fever: an overview. Ann Rheum Dis 2003;62(10):916-19
   PubMed Web of Science ®Google Scholar
• Dotters-Katz S, Kuller J, Price T. The impact of familial Mediterranean fever on women’s health. Obstet Gynecol Surv 2012;67(6):357-64
   PubMed Web of Science ®Google Scholar
• Ehrenfeld EN, Polishuk WZ. Gynecological aspects of recurrent polyserositis (familial Mediterrranean fever, periodic disease). Isr J Med Sci 1970;6(1):9-13
   PubMedGoogle Scholar
• Yanmaz MN, Ozcan AJ, Savan K. The impact of familial Mediterranean fever on reproductive system. Clin Rheumatol 2014;33(10):1385-8
   PubMed Web of Science ®Google Scholar
• Ben-Chetrit A, Ben-Chetrit E, Nitzan R, Ron M. Colchicine inhibits spermatozoal motility in vitro. Int J Fertil Menopausal Stud 1993;38(5):301-4
   PubMed Web of Science ®Google Scholar
• Ehrenfeld M, Levy M, Margalioth EJ, Eliakim M. The effects of long-term colchicine therapy on male fertility in patients with familial Mediterranean fever. Andrologia 1986;18(4):420-6
   PubMed Web of Science ®Google Scholar
• Niel E, Scherrmann JM. Colchicine today. Joint Bone Spine 2006;73(6):672-8
   PubMed Web of Science ®Google Scholar
• Terkeltaub RA, Furst DE, Digiacinto JL, et al. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum 2011;63(8):2226-37
   PubMed Web of Science ®Google Scholar
• Alayli G, Cengiz K, Canturk F, et al. Acute myopathy in a patient with concomitant use of pravastatin and colchicine. Ann Pharmacother 2005;39(7-8):1358-61
   PubMed Web of Science ®Google Scholar
• Atasoyu EM, Evrenkaya TR, Solmazgul E. Possible colchicine rhabdomyolysis in a fluvastatin-treated patient. Ann Pharmacother 2005;39(7-8):1368-9
   PubMed Web of Science ®Google Scholar
• Torgovnick J, Sethi N, Arsura E. Colchicine and HMG Co-A reductase inhibitors induced myopathy-a case report. Neurotoxicology 2006;27(6):1126-7
   PubMed Web of Science ®Google Scholar
• Chen SC, Huang MC, Fan CC. Potentially fatal interaction between colchicine and disulfiram. Prog Neuropsychopharmacol Biol Psychiatry 2009;33(7):1281
   PubMed Web of Science ®Google Scholar
• Goh IX, How CH, Tavintharan S. Cytochrome P450 drug interactions with statin therapy. Singapore Med J 2013;54(3):131-5
   PubMed Web of Science ®Google Scholar
• Finkelstein Y, Aks SE, Hutson JR, et al. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol 2010;48(5):407-14
   PubMed Web of Science ®Google Scholar
• Aghabiklooei A, Zamani N, Hassanian-Moghaddam H, et al. Acute colchicine overdose: report of three cases. Reumatismo 2013;65(6):307-11
   Google Scholar
• Altiparmak MR, Pamuk ON, Pamuk GE, et al. Colchicine neuromyopathy: a report of six cases. Clin Exp Rheumatol 2002;20(4 Suppl 26):S13-16
   Google Scholar
• Dickinson M, Juneja S. Haematological toxicity of colchicine. Br J Haematol 2009;146(5):465
   PubMedGoogle Scholar
• Kuncl RW, Duncan G, Watson D, et al. Colchicine myopathy and neuropathy. N Engl J Med 1987;316(25):1562-8
   PubMed Web of Science ®Google Scholar
• Montseny JJ, Meyrier A, Gherardi RK. Colchicine toxicity in patients with chronic renal failure. Nephrol Dial Transplant 1996;11(10):2055-8
   PubMed Web of Science ®Google Scholar
• Murray SS, Kramlinger KG, McMichan JC, Mohr DN. Acute toxicity after excessive ingestion of colchicine. Mayo Clin Proc 1983;58(8):528-32
   PubMed Web of Science ®Google Scholar
• Borron SW, Scherrmann JM, Baud FJ. Markedly altered colchicine kinetics in a fatal intoxication: examination of contributing factors. Hum Exp Toxicol 1996;15(11):885-90
   PubMed Web of Science ®Google Scholar
• Bismuth C, Fournier PE, Galliot M. Biological evaluation of hemoperfusion in acute poisoning. Clin Toxicol 1981;18(10):1213-23
   PubMed Web of Science ®Google Scholar
• Heaney D, Derghazarian CB, Pineo GF, Ali MA. Massive colchicine overdose: a report on the toxicity. Am J Med Sci 1976;271(2):233-8
   PubMed Web of Science ®Google Scholar
• Demirkol D, Karacabey BN, Aygun F. Plasma exchange treatment in a case of colchicine intoxication. Ther Apher Dial 2015;19(1):95-7
   PubMed Web of Science ®Google Scholar
• Ozdemir R, Bayrakci B, Teksam O. Fatal poisoning in children: acute colchicine intoxication and new treatment approaches. Clin Toxicol 2011;49(8):739-43
   PubMed Web of Science ®Google Scholar
• Baud FJ, Sabouraud A, Vicaut E, et al. Brief report: treatment of severe colchicine overdose with colchicine-specific Fab fragments. N Engl J Med 1995;332(10):642-5
   PubMed Web of Science ®Google Scholar
• Sabouraud A, Urtizberea M, Grandgeorge M, et al. Dose-dependent reversal of acute murine colchicine poisoning by goat colchicine-specific Fab fragments. Toxicology 1991;68(2):121-32
   PubMed Web of Science ®Google Scholar
• Terkeltaub RA. Clinical practice. Gout N Engl J Med 2003;349(17):1647-55
   PubMed Web of Science ®Google Scholar
• Amoura Z, Schermann JM, Wechsler B, et al. Transplacental passage of colchicine in familial Mediterranean fever. J Rheumatol 1994;21(2):383
   PubMed Web of Science ®Google Scholar
• Ben-Chetrit E, Ben-Chetrit A, Berkun Y, Ben-Chetrit E. Pregnancy outcomes in women with familial Mediterranean fever receiving colchicine: is amniocentesis justified? Arthritis Care Res 2010;62(2):143-8
   Web of Science ®Google Scholar
• Ben-Chetrit E, Levy M. Colchicine: 1998 update. Semin Arthritis Rheum 1998;28(1):48-59
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics Committee on D. Transfer of drugs and other chemicals into human milk. Pediatrics 2001;108(3):776-89
   PubMed Web of Science ®Google Scholar
• Piram M, Frenkel J, Gattorno M, et al. A preliminary score for the assessment of disease activity in hereditary recurrent fevers: results from the AIDAI (Auto-Inflammatory Diseases Activity Index) consensus conference. Ann Rheum Dis 2011;70(2):309-14
   PubMed Web of Science ®Google Scholar
• Ozen S, Demirkaya E, Duzova A, et al. FMF50: a score for assessing outcome in familial Mediterranean fever. Ann Rheum Dis 2014;73(5):897-901
   PubMed Web of Science ®Google Scholar
• Ben-Chetrit E, Aamar S. About colchicine compliance, resistance and virulence. Clin Exp Rheumatol 2009;27(2 Suppl 53):S1-3
   Google Scholar
• Ben-Chetrit E, Ozdogan H. Non-response to colchicine in FMF--definition, causes and suggested solutions. Clin Exp Rheumatol 2008;26(4 Suppl 50):S49-51
   Google Scholar
• Seyahi E, Ozdogan H, Celik S, et al. Treatment options in colchicine resistant familial Mediterranean fever patients: thalidomide and etanercept as adjunctive agents. Clin Exp Rheumatol 2006;24(5 Suppl 42):S99-103
   Google Scholar
• Akgul O, Kilic E, Kilic G, Ozgocmen S. Efficacy and safety of biologic treatments in Familial Mediterranean Fever. Am J Med Sci 2013;346(2):137-41
   PubMed Web of Science ®Google Scholar
• Alpay N, Sumnu A, Caliskan Y, et al. Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever. Rheumatol Intern 2012;32(10):3277-9
   PubMed Web of Science ®Google Scholar
• Basaran O, Uncu N, Celikel BA, et al. Interleukin-1 targeting treatment in familial Mediterranean fever: an experience of pediatric patients. Mod Rheumatol 2015;25(4):621-4
   PubMed Web of Science ®Google Scholar
• Bilgen SA, Kilic L, Akdogan A, et al. Effects of anti-tumor necrosis factor agents for familial mediterranean fever patients with chronic arthritis and/or sacroiliitis who were resistant to colchicine treatment. J Clin Rheumatol 2011;17(7):358-62
   PubMed Web of Science ®Google Scholar
• Bilginer Y, Ayaz NA, Ozen S. Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behcet’s disease. Clin Rheumatol 2010;29(2):209-10
   PubMed Web of Science ®Google Scholar
• Bodur H, Seckin U, Eser F, et al. Coexistence of familial Mediterranean fever and psoriasis in a patient with seronegative spondyloarthropathy. Rheumatol Intern 2008;29(1):107-10
   PubMed Web of Science ®Google Scholar
• Calligaris L, Marchetti F, Tommasini A, Ventura A. The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Eur J Pediatr 2008;167(6):695-6
   PubMed Web of Science ®Google Scholar
• Cetin P, Sari I, Sozeri B, et al. Efficacy of interleukin-1 targeting treatments in patients with familial mediterranean Fever. Inflammation 2015;38(1):27-31
   PubMed Web of Science ®Google Scholar
• Daysal S, Akcil G, Goker B, et al. Infliximab therapy in a patient with familial Mediterranean fever and chronic hip arthritis. Arthritis Rheum 2005;53(1):146-7
   PubMed Web of Science ®Google Scholar
• Dinarello CA, van der Meer JW. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol 2013;25(6):469-84
   PubMed Web of Science ®Google Scholar
• Erten S, Erten SF, Altunoglu A. Successful treatment with anti-tumor necrosis factor (anti-TNF)-alpha of proteinuria in a patient with familial mediterranean fever (FMF) resistant to colchicine: anti-TNF drugs and FMF. Rheumatol Int 2012;32(4):1095-7
   PubMed Web of Science ®Google Scholar
• Gattringer R, Lagler H, Gattringer KB, et al. Anakinra in two adolescent female patients suffering from colchicine-resistant familial Mediterranean fever: effective but risky. Eur J Clin Invest 2007;37(11):912-14
   PubMed Web of Science ®Google Scholar
• Hacihamdioglu DO, Ozen S. Canakinumab induces remission in a patient with resistant familial Mediterranean fever. Rheumatology (Oxford) 2012;51(6):1041
   PubMed Web of Science ®Google Scholar
• Kasifoglu T, Bilge SY, Sari I, et al. Amyloidosis and its related factors in Turkish patients with familial Mediterranean fever: a multicentre study. Rheumatology (Oxford) 2014;53(4):741-5
   PubMed Web of Science ®Google Scholar
• Kaya S, Kaptanoglu E, Elden H, Hizmetli S. Coexistence of familial Mediterranean fever and juvenile idiopathic arthritis with osteoporosis successfully treated with etanercept. Intern Med 2010;49(6):619-22
   PubMed Web of Science ®Google Scholar
• Kuijk LM, Govers AM, Frenkel J, Hofhuis WJ. Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra. Ann Rheum Dis 2007;66(11):1545-6
   PubMed Web of Science ®Google Scholar
• Meinzer U, Quartier P, Alexandra JF, et al. Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum 2011;41(2):265-71
   PubMed Web of Science ®Google Scholar
• Metyas S, Arkfeld DG, Forrester DM, Ehresmann GR. Infliximab treatment of Familial Mediterranean fever and its effect on secondary AA amyloidosis. J Clin Rheumatol 2004;10(3):134-7
   PubMed Web of Science ®Google Scholar
• Moll M, Kuemmerle-Deschner JB. Inflammasome and cytokine blocking strategies in autoinflammatory disorders. Clin Immunol 2013;147(3):242-75
   PubMed Web of Science ®Google Scholar
• Mor A, Pillinger MH, Kishimoto M, et al. Familial Mediterranean fever successfully treated with etanercept. J Clin Rheumatol 2007;13(1):38-40
   PubMed Web of Science ®Google Scholar
• Moser C, Pohl G, Haslinger I, et al. Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation. Nephrol Dial Transplant 2009;24(2):676-8
   PubMed Web of Science ®Google Scholar
• Nakamura A, Matsuda M, Tazawa K, et al. Successful treatment with infliximab and low-dose methotrexate in a Japanese patient with familial Mediterranean fever. Intern Med 2007;46(15):1247-9
   PubMed Web of Science ®Google Scholar
• Ozcakar ZB, Ozdel S, Yilmaz S, et al. Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis. Clin Rheumatol 2014. [Epub ahead of print]
   Google Scholar
• Ozen S, Bilginer Y, Aktay Ayaz N, Calguneri M. Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. J Rheumatol 2011;38(3):516-18
   PubMed Web of Science ®Google Scholar
• Ozgocmen S, Akgul O. Anti-TNF agents in familial Mediterranean fever: report of three cases and review of the literature. Mod Rheumatol 2011;21(6):684-90
   PubMed Web of Science ®Google Scholar
• Ozgocmen S, Ozcakar L, Ardicoglu O, et al. Familial Mediterranean fever responds well to infliximab: single case experience. Clin Rheumatol 2006;25(1):83-7
   PubMed Web of Science ®Google Scholar
• Petropoulou AD, Robin M, Socie G, Galicier L. Transmission of familial Mediterranean fever mutation after bone marrow transplantation and successful treatment with anakinra. Transplantation 2010;90(1):102-3
   PubMed Web of Science ®Google Scholar
• Roldan R, Ruiz AM, Miranda MD, Collantes E. Anakinra: new therapeutic approach in children with Familial Mediterranean Fever resistant to colchicine. Joint Bone Spine 2008;75(4):504-5
   PubMed Web of Science ®Google Scholar
• Sakallioglu O, Duzova A, Ozen S. Etanercept in the treatment of arthritis in a patient with familial Mediterranean fever. Clin Exp Rheumatol 2006;24(4):435-7
   PubMed Web of Science ®Google Scholar
• Soriano A, Verecchia E, Afeltra A, et al. IL-1beta biological treatment of familial Mediterranean fever. Clin Rev Allergy Immunol 2013;45(1):117-30
   PubMed Web of Science ®Google Scholar
• Stankovic Stojanovic K, Delmas Y, Torres PU, et al. Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Nephrol Dial Transplant 2012;27(5):1898-901
   PubMed Web of Science ®Google Scholar
• Yuksel S, Yalcinkaya F, Acar B, et al. Clinical improvement with infliximab in a child with amyloidosis secondary to familial Mediterranean fever. Rheumatology (Oxford) 2006;45(10):1307-8
   PubMed Web of Science ®Google Scholar
• Zihni FY, Kalfa M, Ocakci PT, et al. Coexistence of Takayasu’s arteritis with familial Mediterranean fever. Rheumatol Int 2012;32(6):1675-8
   PubMed Web of Science ®Google Scholar
• Eroglu FK, Besbas N, Topaloglu R, Ozen S. Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents. Rheumatol Int 2015. [Epub ahead of print]
   Google Scholar
• Chae JJ, Cho YH, Lee GS, et al. Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1beta activation and severe autoinflammation in mice. Immunity 2011;34(5):755-68
   PubMed Web of Science ®Google Scholar
• Ben-Zvi I, Livneh A. Colchicine failure in familial Mediterranean fever and potential alternatives: embarking on the anakinra trial. Isr Med Assoc J 2014;16(5):271-3
   PubMed Web of Science ®Google Scholar
• Rossi-Semerano L, Fautrel B, Wendling D, et al. Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey. Orphanet J Rare Dis 2015;10:19
   PubMed Web of Science ®Google Scholar
• Yang BB, Baughman S, Sullivan JT. Pharmacokinetics of anakinra in subjects with different levels of renal function. Clin Pharmacol Ther 2003;74(1):85-94
   PubMed Web of Science ®Google Scholar
• Brik R, Butbul-Aviel Y, Lubin S, et al. Canakinumab for the treatment of children with colchicine-resistant familial mediterranean Fever: a 6-month open-label, single-arm pilot study. Arthritis Rheum 2014;66(11):3241-3
   PubMed Web of Science ®Google Scholar
• Sozeri B, Kasapcopur O. Biological agents in familial mediterranean Fever focusing on colchicine resistance and amyloidosis. Curr Med Chem 2015;22(16):1986-91
   PubMed Web of Science ®Google Scholar
• Kuemmerle-Deschner JB, Haug I. Canakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians. Ther Adv Musculoskelet Dis 2013;5(6):315-29
   PubMedGoogle Scholar
• Baldo BA. Chimeric fusion proteins used for therapy: indications, mechanisms, and safety. Drug Saf 2015;38(5):455-79
   PubMed Web of Science ®Google Scholar
• Hashkes PJ, Spalding SJ, Hajj-Ali R, et al. The effect of rilonacept versus placebo on health-related quality of life in patients with poorly controlled familial Mediterranean fever. BioMed Res Int 2014;2014:854842
   PubMed Web of Science ®Google Scholar
• Hashkes PJ, Huang B. The familial Mediterranean fever (FMF) 50 score: does it work in a controlled clinical trial? Re-analysis of the trial of rilonacept for patients with colchicine-resistant or intolerant FMF. Isr Med Assoc J 2015;17(3):137-40
   PubMed Web of Science ®Google Scholar
• Ben-Zvi I, Livneh A. Chronic inflammation in FMF: markers, risk factors, outcomes and therapy. Nat Rev Rheumatol 2011;7(2):105-12
   PubMed Web of Science ®Google Scholar
• Schwabe AD, Peters RS. Familial Mediterranean Fever in Armenians. Analysis of 100 cases. Medicine 1974;53(6):453-62
   PubMed Web of Science ®Google Scholar
• Tankurt E, Tunca M, Akbaylar H, Gonen O. Resolving familial Mediterranean fever attacks with interferon alpha. Br J Rheumatol 1996;35(11):1188-9
   PubMedGoogle Scholar
• Tunca M, Akar S, Soyturk M, et al. The effect of interferon alpha administration on acute attacks of familial Mediterranean fever: A double-blind, placebo-controlled trial. Clin Exp Rheumatol 2004;22(4 Suppl 34):S37-40
   Google Scholar
• Tunca M, Tankurt E, Akbaylar Akpinar H, et al. The efficacy of interferon alpha on colchicine-resistant familial Mediterranean fever attacks: a pilot study. Br J Rheumatol 1997;36(9):1005-8
   PubMedGoogle Scholar
• Soriano A, Manna R. Familial Mediterranean fever: new phenotypes. Autoimmun Rev 2012;12(1):31-7
   PubMed Web of Science ®Google Scholar
• Akkoc N, Gul A. Familial Mediterranean fever and seronegative arthritis. Curr Rheumatol Rep 2011;13(5):388-94
   PubMed Web of Science ®Google Scholar
• Brik R, Shinawi M, Kasinetz L, Gershoni-Baruch R. The musculoskeletal manifestations of familial Mediterranean fever in children genetically diagnosed with the disease. Arthritis Rheum 2001;44(6):1416-19
   PubMed Web of Science ®Google Scholar
• Kasifoglu T, Calisir C, Cansu DU, Korkmaz C. The frequency of sacroiliitis in familial Mediterranean fever and the role of HLA-B27 and MEFV mutations in the development of sacroiliitis. Clin Rheumatol 2009;28(1):41-6
   PubMed Web of Science ®Google Scholar
• Bakkaloglu SA, Aksu T, Goker B, et al. Sulphasalazine treatment in protracted familial Mediterranean fever arthritis. Eur J Pediatr 2009;168(8):1017-19
   PubMed Web of Science ®Google Scholar
• Estublier C, Stankovic Stojanovic K, Bergerot JF, et al. Myositis in a patient with familial Mediterranean fever and spondyloarthritis successfully treated with anakinra. Joint Bone Spine 2013;80(6):645-9
   PubMed Web of Science ®Google Scholar
• Mercan R, Turan A, Bitik B, et al. Rapid resolution of protracted febrile myalgia syndrome with anakinra: Report of two cases. Mod Rheumatol 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• El-Shanti HI. Familial mediterranean Fever and renal disease. Saudi J Kidney Dis Transpl 2003;14(3):378-85
   PubMedGoogle Scholar
• Saatci U, Bakkaloglu A, Ozen S, Besbas N. Familial Mediterranean fever and amyloidosis in children. Acta Paediatr 1993;82(8):705-6
   PubMed Web of Science ®Google Scholar
• Gershoni-Baruch R, Brik R, Lidar M, et al. Male sex coupled with articular manifestations cause a 4-fold increase in susceptibility to amyloidosis in patients with familial Mediterranean fever homozygous for the M694V-MEFV mutation. J Rheumatol 2003;30(2):308-12
   PubMed Web of Science ®Google Scholar
• Ozen S, Aktay N, Lainka E, et al. Disease severity in children and adolescents with familial Mediterranean fever: a comparative study to explore environmental effects on a monogenic disease. Ann Rheum Dis 2009;68(2):246-8
   PubMed Web of Science ®Google Scholar
• Migita K, Agematsu K, Masumoto J, et al. The contribution of SAA1 polymorphisms to Familial Mediterranean fever susceptibility in the Japanese population. PLoS One 2013;8(2):e55227
   Web of Science ®Google Scholar
• Mukhin NA, Kozlovskaya LV, Bogdanova MV, et al. Predictors of AA amyloidosis in familial Mediterranean fever. Rheumatol Int 2015;35(7):1257-61
   PubMed Web of Science ®Google Scholar
• Hamanoue S, Suwabe T, Hoshino J, et al. Successful treatment with humanized anti-interleukin-6 receptor antibody (tocilizumab) in a case of AA amyloidosis complicated by familial Mediterranean fever. Mod Rheumatol 2015. [Epub ahead of print]
   PubMedGoogle Scholar
• Ozen S, Demirkaya E, Amaryan G, et al. Results from a multicentre international registry of familial Mediterranean fever: impact of environment on the expression of a monogenic disease in children. Ann Rheum Dis 2014;73(4):662-7
   PubMed Web of Science ®Google Scholar